Group 1 - Shouhui Group has officially launched its IPO, offering approximately 24.36 million shares at a price range of HKD 6.48 to HKD 8.08 per share, with a listing date expected on May 30 [1] - The funds raised from the IPO will be used for optimizing the sales network, R&D investment, and acquisitions, which will enhance the company's market competitiveness and business scale [1] Group 2 - Heng Rui Pharmaceutical's shares surged by 32.24% in the dark market, closing at HKD 58.25 after an initial offering price of HKD 44.05, indicating strong market confidence in its future [2] - The company reported a revenue of 27.985 billion yuan for 2024, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% from the previous year [2] Group 3 - Wei Hong Group Holdings expects a net loss of approximately 48.5 million Macanese Patacas for the fiscal year 2024, compared to a net loss of about 27.8 million Macanese Patacas in 2023, attributed to a decline in revenue [3] - The group's revenue for the reporting year is expected to be around 9.7 million Macanese Patacas, down from approximately 105.8 million Macanese Patacas in the previous year [3] Group 4 - Longqi Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its capital strength and international brand image, supporting its global business development [4] - The issuance will be subject to approval from the shareholders' meeting and relevant government and regulatory bodies [4] Group 5 - The Hang Seng Index closed at 23,544.31, down 1.19%, while the Hang Seng Tech Index fell by 1.70% to 5,251.75 [5] - The Yuqi Index also decreased by 1.19%, closing at 8,557.64 [5]

Core Viewpoint - The recent IPOs in the Hong Kong stock market have shown strong profitability, with significant price increases for newly listed stocks like 恒瑞医药 (Hengrui Medicine) and MIRXES-B during the dark pool trading period [1][2]. Company Summaries 恒瑞医药 (Hengrui Medicine) - 恒瑞医药, an established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D expenditure of 29.4% of total revenue in 2024 [6]. - The company has returned approximately RMB 80.29 billion in cash dividends to shareholders since its A-share listing, which is 16.8 times the capital raised at that time [6]. - 恒瑞医药 has 19 marketed innovative drugs and over 90 new molecular entities in clinical or later stages of development [6]. - The total revenue for 恒瑞医药 is projected to be RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of about 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of approximately 4% [6]. - The revenue contribution from innovative drugs increased from 38.1% in 2022 to 43.4% in 2023, and is expected to reach 46.3% in 2024, while the contribution from generic drugs decreased from 60.3% in 2022 to 42.0% in 2024 [7]. MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in microRNA technology for disease screening and diagnostics, particularly in cancer detection [7]. - The company is one of the few globally to have received regulatory approval for molecular cancer screening IVD products, and is the first to receive such approval for molecular gastric cancer screening [7]. - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [7]. - The subscription multiple for MIRXES-B is significantly lower than that of 恒瑞医药, with 25 times compared to 恒瑞医药's 409 times [7]. Market Trends - The recent trend in the Hong Kong IPO market shows a strong upward movement, with only 6 out of 23 newly listed companies this year experiencing a decline on their first trading day, while others have seen substantial gains [8].

Core Viewpoint - The article highlights the significant price increases of two new stocks, 恒瑞医药 (Hengrui Medicine) and MIRXES-B, during the dark trading period before their listing on the Hong Kong stock market, indicating strong market interest and potential investment opportunities. Group 1: Hengrui Medicine - Hengrui Medicine, a well-established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D investment of 29.4% of total revenue in 2024 [3] - The company has a diverse portfolio with 19 marketed innovative drugs and over 90 in clinical or later stages of development [4] - Hengrui's total revenue is expected to reach RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of approximately 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of about 4% [4] - The sales revenue from innovative drugs has increased from 38.1% of total revenue in 2022 to 43.4% in 2023, and is projected to reach 46.3% in 2024, while sales from generic drugs are decreasing [4] Group 2: MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in miRNA technology for disease screening and diagnostics, particularly in cancer detection [4] - The company is one of the few globally to have received regulatory approval for its molecular cancer screening IVD products, including the first approval for molecular gastric cancer screening [4] - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [5] - The subscription ratio for MIRXES-B is significantly lower than that of Hengrui Medicine, with 25 times compared to Hengrui's 409 times [6]

Group 1 - The core viewpoint of the article highlights a surge in H-share listings by leading A-share companies, with significant capital inflow into the Hong Kong market, driven by international investors' re-evaluation of Chinese assets [1][2] - The recent IPO boom in Hong Kong has raised a total of HKD 145 billion in the past year, marking a 2.7 times increase year-on-year, with major contributions from companies like Ningde Times and Midea Group [2] - The previous IPO wave in Hong Kong, initiated by Alibaba's return in November 2019, lasted nearly three years, indicating a cyclical trend in capital movements and market sentiment [1][2] Group 2 - The top ten IPOs in Hong Kong predominantly come from mainland China, contributing 75% of the total fundraising, showcasing the dominance of A-share companies in the Hong Kong market [2] - The Hong Kong Stock Exchange experienced over HKD 1 trillion in IPO financing from 2019 to 2021, with 2019 being the peak year with 183 IPOs raising HKD 312.7 billion [2] - The recent market rally in Hong Kong, with an increase of nearly 5000 points since April 9, suggests a positive outlook for the medium to long term, driven by continued capital inflow and the entry of more quality companies [1]

恒瑞医药（600276.SH）将于明日正式在港交所上市，成为又一"A+H"两地上市的国内大药企。 5月22日，恒瑞医药（01276.HK）正在暗盘交易中，截至16时36分，股价涨超27%，报56.15港元/股， 不计手续费，中签一手（200股）赚超2400港元，最新总市值超3700亿港元。 据悉，暗盘交易又称为场外交易，指不通过港交所交易系统撮合，而直接在某些大型券商内部交易系统 实现报价撮合的交易，为港股市场特有的一种交易方式。 > 招股书显示，恒瑞医药本次拟全球发售约2.25亿股，香港公开发售占比 5.5%，国际发售占比 94.5%，上 市发行定价为 44.05 港元/股。 此次恒瑞医药H股发行获得国际资本青睐，基石投资者涵盖新加坡政府投资公司（GIC）、景顺 （Invesco）、瑞银全球资产管理集团（UBS-GAM）、高瓴资本、博裕资本等知名机构。 国证国际证券此前发布的研报指出，恒瑞医药此次IPO发行价为41.45—44.05港元，较A股股价有24%— 28%的折价，对应2024年PE为40x—42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股 市场打新热情较为高涨，综合考虑给予IPO专 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-082 江苏恒瑞医药股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司山东盛迪医 药医药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发 的《药品注册证书》，批准公司自主研发的 1 类创新药瑞格列汀二甲双胍片（Ⅰ） /（Ⅱ）上市，适应症为：本品配合饮食控制和运动，适用于适合接受磷酸瑞格 列汀和盐酸二甲双胍治疗的 2 型糖尿病成人患者改善血糖控制。该产品是中国首 个自主研发的二肽基肽酶-4 抑制剂（DPP-4i）联合二甲双胍固定复方制剂。现 将相关情况公告如下： 一、药品的基本情况 药品名称：瑞格列汀二甲双胍片（Ⅰ）/（Ⅱ） 剂型：片剂 规格：50mg/850mg 和 50mg/1000mg 注册分类：化学药品 1 类 受理号：CXHS2300011、CXHS2300012 处方药/非处方药：处方药 审批结论：根据《中华人民共和国药品管理办法》及有关规 ...

Core Viewpoint - Heng Rui Medicine (600276) announced that its subsidiary, Shandong Shengdi Medicine, has received approval from the National Medical Products Administration for the drug registration certificate of its self-developed innovative drug, Regaglitin Metformin Tablets, marking a significant milestone in the company's product pipeline [1] Group 1: Product Development - The innovative drug is indicated for the treatment of adult patients with type 2 diabetes to improve blood glucose control when used in conjunction with diet and exercise [1] - Regaglitin Metformin Tablets are the first self-developed DPP-4 inhibitor combined with metformin fixed-dose formulation in China [1] - The total research and development investment for the Regaglitin Metformin Tablets project has reached approximately 76.6 million yuan [1]

恒瑞医药股价在香港暗盘交易中涨近28%。公司港股定价44.05港元，23日登陆港交所。 ...

恒瑞医药(01276.HK)今日暗盘开盘涨超27%，报56.15港元，开盘价为49港元。 ...

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a resurgence, with notable performances from companies like Sanofi and the launch of Heng Rui Pharmaceutical's H-shares in Hong Kong [1][3] - The Tianhong Innovative Drug ETF has seen a continuous increase for seven days, indicating strong investor interest in the innovative drug sector [1][2] - Heng Rui Pharmaceutical has set its H-share issuance price at HKD 44.05, which is the upper limit of the expected price, reflecting positive market sentiment towards A-share companies listing in Hong Kong [1] Group 2 - The Biopharmaceutical ETF closely tracks the Guozheng Biopharmaceutical Index, which includes the top 30 companies in the biopharmaceutical industry based on market capitalization and liquidity [2] - The Tianhong Innovative Drug ETF tracks the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug 50 Index, which selects 50 leading innovative drug companies across three markets [2] - The innovative drug sector is expected to remain a core focus for the pharmaceutical industry, supported by policy backing and increasing global competitiveness [3]